Viking Therapeutics

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Our mission is to discover and develop innovative medicines that help make a meaningful difference in people’s lives.

Our vision is to be the premier biopharmaceutical company dedicated to the development of life-enhancing therapies for metabolic and endocrine diseases.

Viking Therapeutics has earned numerous awards and recognitions, including the San Diego Mergers and Acquisitions Best Life Science Company 2017, the Orange County Business Journal Top Emerging Company of 2016, and the San Diego Business Journal Best Emerging Life Science Company of 2016.